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ABSTRACT
Background: Chronic kidney disease (CKD) affects both dogs and cats, mainly elderly animals, due to tubulointerstitial 
inflammation associated with the increase of fibrosis through the excess deposition of extracellular matrix (ECM) which 
leads to decrease glomerular filtration. Many different underlying renal diseases can affect the kidneys of dogs such as 
congenital or acquired in origin. Therefore, the main objective of this transversal study was to evaluate the epidemiology 
through clinical and laboratory evaluation of 225 client-owned dogs with CKD.
Materials, Methods & Results: Complete blood count (CBC), urinalysis, and biochemical profile were retrospectively 
selected and evaluated from 225 client-owned dogs with CKD of both sexes, different ages, and breeds from the patient 
population of the Nephrology and Urology Small Animal Service of the Teaching Hospital of the School of Veterinary 
Medicine and Animal Science - São Paulo State University from 2011 to 2017. All dogs were divided in groups accord-
ing to the International Renal Interest Society (IRIS) CKD grading and statistical analysis was performed according to 
Kruskal-Wallis non-parametric test complemented with Dunn’s multiple comparisons test, and analysis of variance for the 
model with a factor complemented with the test of multiple comparisons of Tukey. In this retrospective study, we observed 
that most dogs in all groups were elderly (≥ 9 years old). CBC demonstrated lower RBC’s (P < 0.005), hemoglobin (P < 
0.001), hematocrit (Ht%) [P < 0.001] at the highest stage of the disease. However, urinary specific gravity (USG) did not 
demonstrate significant differences between the disease stages, but urinary protein: creatinine ratio (UPC) was statisti-
cally different (P < 0.01) between IRIS-CKD stages 1 and 4. Furthermore, serum phosphate concentrations demonstrated 
significantly higher levels in dogs at IRI-CKD stage 4 compared with IRIS-CKD stage 3 (P < 0.001).
Discussion: The analysis of 225 dogs with CKD showed that 130 animals were elderly, older than 9 years, and according 
to previous studies, 15% of dogs over 10 years of age are diagnosed of CKD, presenting significant morbidity and mor-
tality. Laboratory findings such as the presence of non-regenerative anemia is expected in dogs with CKD. In our study, 
the degree of anemia corresponded with the stage of the disease, similarly to serum creatinine concentrations. Another 
important laboratory finding in diagnosing CKD is the early detection of the kidney’s abilities in concentrating its tubular 
filtrate. In this retrospective study, isosthenuria was not significant due to all dogs presented CKD as criteria of inclusion, 
especially those without azotemia, although, proteinuria was reported in 90% of the population investigated. Electrolyte 
imbalances are also expected in CKD. However, despite serum sodium, potassium, and total calcium did not demonstrate 
significant results, serum phosphate had its significance between IRIS-CKD stage 3 and stage 4. Hence, despite the age 
factor of most dogs in all groups, with the association of laboratory results such as serum creatinine, serum phosphorus, 
ionized calcium, erythrogram, isosthenuria, SBP, and the degree of proteinuria, it was possible to perform early diagnosis 
of CKD even in dogs with IRIS-CKD Stage 1 in a stable and hydrated patient. With the proper diagnostic, staging and 
substaging according to IRIS guidelines, these parameters can be monitored, predicting longevity and good quality of life, 
or progression of the disease with a more reserved prognosis.
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INTRODUCTION
Chronic Kidney Disease (CKD) is a global di-
sease for humans, as well as for dogs and cats [4,20,42]. 
Each species has its own nephropathy particularities, 
although the progressive and irreversible loss of kidney 
function is a common ending point [4,20,42]. Furthermo-
re, chronic tubulointerstitial nephritis and kidney fibrosis 
are the main responsible factors for loss of renal function, 
and thus leading to a progressive renal dysfunction [27]. 
This nephropathy usually presents a long pro-
gression time (2 to 3 months) until the onset of clinical 
signs associated with azotemia [4,38,41], which can 
delay the diagnosis and, thus, reducing the survival rate 
of these animals [4,41,43]. Despite clinical signs are 
mostly non-specific, such as polyuria and polydipsia 
[4,12,26,32,43,45], laboratory findings and imaging 
exams, particularly the ultrasonography, improves the 
accuracy for its diagnosis because its etiology is very 
difficult to determine, and it still relies on the biopsy 
as a gold standard diagnostic [4,36]. 
According to the International Renal Interest 
Society (IRIS), dogs with CKD are classified into 4 
stages [22]. Its classification is based on the serum 
concentrations of creatinine, and most recently, in 
serum symmetric dimethylarginine (IDEXX SDMA)1 
concentration. Additionally, its sub-classification is 
based on proteinuria and blood pressure, contributing 
to proper diagnosis, prognosis, and treatments [22,41].
The aim of this retrospective study was to per-
form a comparative clinical, etiological and laboratory 
analysis of dogs with chronic kidney disease treated at 
the Teaching Veterinary Hospital of School of Veteri-
nary Medicine and Animal Science - São Paulo State 
University (UNESP) from 2011 to 2017.
MATERIALS AND METHODS
Animal data collection
Data from 225 client-owned dogs from both 
sexes, of different ages, and breeds were retrospectively 
selected from the patient population of the Nephrology 
and Urology Small Animal Service of the Teaching Hos-
pital of the School of Veterinary Medicine and Animal 
Science - São Paulo State University from 2011 to 2017.
Selection criteria
The selection criteria for inclusion of the ani-
mals were based on the complete history, compatible 
clinical signs to the disease, laboratory exams such as 
CBC (PocH-100iv Diff, Sysmex)2, urinalysis, and bio-
chemical profile (Cobas Mira Plus, Roche)3, Systolic 
Blood Pressure (SBP) was  monitored by non-invasive 
Doppler (Doppler Ultrasound device)4, and abdominal 
ultrasonographic evaluation (Mylab AlphaVET, Esa-
ote)5. Dogs diagnosed with concurrent AKI, sepsis, 
pancreatitis, coagulation disorder, infectious disease, 
and nephrolithiasis or had a previous history of familial 
or congenital renal disease, congestive heart failure, 
autoimmune disease, and neoplasia were automatically 
excluded from the study.
After selection, all dogs were diagnosed and 
substage according to the IRIS guidelines [22] and 
divided into four groups to simplify the comparative 
aspects of the study and to grant better results. All data 
were present with the median and interquartile ratio of 
each category in each group. 
Statistical analysis
Statistical analysis was performed according 
to Kruskal-Wallis non-parametric test complemented 
with Dunn’s multiple comparisons test [57]. Also, the 
technique of analysis of variance for the model with 
a factor complemented with the test of multiple com-
parisons of Tukey [57]. All discussions of the results 
of the statistical tests were performed at the 5% level 
of significance.
RESULTS
The analysis of 225 dogs with CKD demons-
trated that 130 animals were elderly and older than 
9 years. There was a significant difference between 
the mean ages between IRIS-CKD stage 1 and 2 with 
IRIS-CKD stage 3 and 4 (P < 0.005), but the mean was 
lower in IRIS CKD stage 3 and 4 (9,2 and 8,9 years 
respectively) [Table 1]. Although, sex distribution was 
homogeneous with no statistical significance betwe-
en dogs with different stages of CKD, according to 
Goodman’s Homogeneity Test [Table 1].
The worst exam results were at the highest 
stage of CKD, especially for RBC’s (P < 0.005), he-
moglobin (P < 0.001), and Ht% (P < 0.001) [Table 2]. 
In the present study, all dogs had a damaged kidney 
function with high values of serum urea and creatinine 
concentrations and, as expected, it was significant ac-
cording to the stage of the disease (P < 0.001) [Table 3].
According to the urinalysis values despite USG 
did not demonstrated significant differences between 
stages, urinary pH had small significant difference 
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between stages with an increase of its pH (P < 0.05) 
[Table 4]. Although urine culture was not performed 
in this study, urinary protein detected in the dipstick 
did increase as well along stages, thus revealing a sig-
nificant difference between stage 1 and 4 (P < 0.01). 
Additionally, in this study, approximately 90% of dogs 
had proteinuria. The urinary protein: creatinine ratio 
(UPC) of dogs on IRIS-CKD stages 1 and 4 were sta-
tistically different (P < 0.01); furthermore, we observed 
that the higher the protein loss, the higher stage of the 
disease was, seen as a significant difference especially 
between stages 3 and 4 (P < 0.05) [Table 5].
In respect of electrolytes concentrations, 
phosphate concentrations were significantly higher in 
dogs at IRIS stage 4 compared with IRIS stage 3 (P 
< 0.001) [Table 3]. Notwithstanding, some data did 
not present significant differences such as USG, SBP, 
serum total calcium, sodium and potassium concentra-
tions, requiring a longer follow up evaluation during 
the progression of the disease (P > 0.05).
DISCUSSION
As mentioned before, breed and age may 
represent relevant risk factors which contribute to 
the onset of the disease by either genetic factors and 
the presence of concomitant disease [20,38,41]. The 
analysis of 225 dogs with CKD showed 130 animals 
were elderly, older than 9 years. This result corrobora-
tes with the literature and shows the chronicity of the 
disease. According to studies, 15% of dogs over 10 
years of age suffer from CKD, presenting significant 
morbidity and mortality [53].
The age of the patients is one of the main 
variables to be analyzed because the disease occurs 
mainly in elderly animals, although, in our study 
younger animals were in an advanced stage of the 
disease (Table 1).
The progression of the disease was also acces-
sed by comparing the ages of the dogs with all IRIS 
stages as shown in Table 1. This finding shows that 
CKD contributes with the decrease of life expectancy. 
However, other authors showed that age of animals 
with CKD may not differ among different etiologies 
[28] and in elderly animals it is more severe [31].
Some risk factors as breed and sex may vary 
between the studies; Breed, for instance, may represent 
a confounding variable, since it may vary according to 
the location of the study [21,29,38,50,58]. In this study, 
most of the animals were mixed breed. The authors 
have attributed it of some country bias, since it is one 
of the most common breeds in Brazil [5,8,14,24,30,48].
In respect of CBC, non-regenerative anemia 
is one of the common findings in dogs with CKD 
[3,16,46]. In accordance with literature, the present 
data demonstrated that all groups presented a nor-
mocytic and normochromic anemia (Table 2) [25]. 
Notwithstanding, and according to other authors, there 
was no difference regarding the predictors of regenera-
tion among the stages of the disease [9]. The presence 
of inflammation and the increase of oxidative stress 
plays an important role during the progression of CKD 
[7,35,49]; furthermore, uremia contributes negatively 
on the lifespan of RBCs and to iron deficiency; Also, 
if uremia is not treated, uremic thrombocytopathia can 
also intensify the degree of anemia [44].
The most common worldwide and available 
biomarker to evaluate kidney function is serum creati-
nine. Additionally, concentrations of serum urea is ano-
ther biomarker responsible in monitoring the retention 
of nitrogen metabolites that should be excreted by the 
nephrons, both biomarkers when associated reflects the 
renal function [33,38,43]. In the present study, all dogs 
had a compromised kidney function with an elevation 
of creatinine concentration as expected (Table 3).
The renin-angiotensin system is correlated 
with creatinine increasing and decrease of glomerular 
filtration which contribute to the progression of the 
disease [34]. Another parameter to be considered to 
the progression of the disease is the urea concentration 
at the diagnosis, it may be a predictor of survival time 
during the CKD progression (Table 3) [22].
During the past years, new studies are focusing 
on earlier renal disease biomarkers such as SDMA 
[47,56]. A small amino acid that is mainly secreted 
by the kidneys, making it sensitive to evaluate GFR 
and allows early diagnosis of CKD when compared to 
serum creatinine [10,18,37]. Due to the start date of this 
study and the standardization of all animals evaluated, 
it was not possible to perform the SDMA evaluation. 
Unfortunately, it was added to the IRIS CKD guide-
lines after the beginning of this project which made 
SDMA dosage impossible.
Hyperphosphatemia in dogs with CKD is as-
sociated with an imbalance in its intestinal absorption, 
renal excretion and bone absorption [39,47,48]. Phos-
phate evaluation and management is important at the 
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Table 1. Distribution of the mean, standard deviation of age and absolute sex frequency within each CKD stag-
ing of canines attended at TH-FMVZ-UNESP in the period 2011-2017.
Parâmetro IRIS-CKD Stages1 2 3 4 Value P
Age (years) 11.94 ± 3, 01 11.42 ± 3.46 9.23 ± 4.08 8.97 ± 3.73 P < 0.005
Sex Total
Female 7 14 37 51 109
Male 10 12 54 40 116
Total 17 26 91 91 225
Table 2. Distribution of mean and standard deviation (with lowest and highest value, respectively) of the analysis 
of the complete blood count of each IRIS-CKD stage of the canines attended at the TH-FMVZ-UNESP in the 
period of 2011-2017.
Parâmetro
IRIS-CKD Stages
1 2 3 4 P value
Red Blood Cells (x106/μL) 4.60 ± 1.60 4.52 ± 1.48 3.76 ± 1.25 3.56 ± 1.13 P < 0.005
Hemoglobin (g/dL) 11.15 ± 3.54 10.68 ± 2.96 9.13 ± 2.84 8.86 ± 3.05 P < 0.001
Ht (%) 32.94 ± 10.67 30.35 ± 8.06 26.26 ± 7 , 71 25.53 ± 8.14 P < 0.001
MCV (fL) 70.93 ± 8.72 68.39 ± 9.99 70.70 ± 7.28 70.47 ± 6.14 P > 0.05
MCHC (%) 33.85 ± 2.56 35.05 ± 3.58 34.76 ± 2.91 34.97 ± 3.27 P > 0.05
RDW 12.40 ± 3.96 14.16 ± 4.11 13.69 ± 2.93 13.69 ± 2.96 P > 0.05
PT (Plasma) (g/dL) 7.14 ± 0.97 7.85 ± 1.19 7.54 ± 1.51 7.94 ± 1.23 P > 0.05
Platelets (x103/μL) 327.6 ± 168.0 319.8 ± 193.8 305.3 ± 190.3 251.2 ± 149.8 P > 0 05
WBC (x103/uL) 10.2 (6.2; 25.0) 9.1 (5.6; 359.0) 10.3 (3.2; 54.1) 10.8 (2.1; 30.4) P > 0.05
Table 3. Distribution of the mean and standard deviation (with lowest and highest values, respectively) of the 
complete biochemical analysis of each IRIS-CKD stage of the canines attended at TH-FMVZ-UNESP in the 
period 2011-2017.
Parâmetro
IRIS-CKD Stages
1 2 3 4 P value
Urea (mg/dL) 83.09 ± 47.17 97.43 ± 39.29 188.02 ± 117.77 312.60 ± 160, 79 P < 0.001
Creatinine (mg/dL) 1.09 ± 0.23 1.77 ± 0.17 3.43 ± 0.89 9.78 ± 6.91 P < 0.001
Albumin (g/dL) 2.65 (1.80; 9.70) 2.55 (1.30; 5.90) 2.40 (0.90; 11.3) 2.50 (0.10; 13.50) P > 0.05
Total Calcium (mg/dL) 8.51 ± 2.25 10. 82 ± 1.73 10.19 ± 2.94 9.68 ± 2.68 P > 0.05
Phosphorus (mg/dL) 4.47 ± 1.27 6.30 ± 4.78 9.48 ± 7.04 19.19 ± 15.13 P < 0.001
Sodium (mEq/L) 147.64 ± 12.83 143.07 ± 30.64 21.98 143.70 ± 145.22 ± 11.18 P > 0.05
Potassium (mEq/L) 4.20 ± 0.85 4.69 ± 1.10 4.75 ± 1.41 4.80 ± 1.55 P > 0.05
Table 4. Distribution of the mean and standard deviation (with lowest and highest value, respectively) of the 
urinalysis of each IRIS-CKD stages of the canines attended at TH-FMVZ-UNESP in the period 2011-2017.
Parâmetro
IRIS-CKD Stages
1 2 3 4 Value P
pH 6.50 ± 1.12 6.12 ± 1.09 5.91 ± 0.78 5.87 ± 0.85 P < 0.05
Specific Gravity 1.013 (0.005) 1.014 ± 0.004 1.014 ± 0.004 1.014 ± 0.010 P > 0.05
Protein 0.91 ± 0.62 1.19 ± 0.87 1.70 ± 0.86 1.69 ± 0.86 P < 0.01
Glucose 0.0 (0.0; 0.0) 0 0 (0.0; 3.0) 0.0 (0.0; 1.0) 0.0 (0.0; 2.0) P > 0.05
Ketone Bodies 0.0 (0.0; 0.0) 0.0 (0.0; 0.0) 0.0 (0.0; 0.0) 0.0 (0.0; 0.0) P > 0.05
Urobilinogen 0.0 (0.0; 1.0) 0.0 (0.0; 1.0) 0.0 (0.0; 1.0) 0.0 (0.0; 1.0) P > 0.05
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diagnosis of CKD, and it is one of the main triggering 
factors for secondary renal hyperparathyroidism con-
tributing to bone demineralization and mineralization 
of other tissues [11,19,40].
Furthermore, as kidney function decreases, 
PTH and the renal excretion of phosphate increases, 
leading to the activation of calcitriol from calcidiol 
even in earlier stages of the disease [11,13,19,40]. The 
significant hyperphosphatemia in dogs at IRIS-Stage 
4 represents a higher risk to develop mineral and bone 
disorders as the diseases progresses (Table 3). Thus, 
it would be interesting to carry out statistical com-
parisons between the phosphate and ionized calcium 
concentrations among the same groups, proving that 
ionized hypocalcemia is linked to hyperphosphatemia.
Ionized hypocalcemia is another laboratorial 
finding in dogs with CKD [13]. Its occurrence can 
be associated with hyperphosphatemia, low vitamin 
D production by the kidneys, calcium deposition in 
other organs, and low absorption of calcium via gas-
trointestinal tract [15,39]. In the present study, most 
dogs presented normal serum total calcium (tCa) con-
centrations (Table 3); However, tCa does not support 
as a correct diagnosis as well as for monitoring bone 
and mineral disorders. Total calcium is composed 
of ionized calcium (iCa), complexed calcium, and 
protein-bound calcium; Hence, ionized hypocalcemia 
should be considered in dogs with advanced CKD [13].
In addition to the hematological, biochemical 
exams and clinical signs, the reduction in renal func-
tion was also saw by the lower urinary specific gravity 
(USG) through the urinalysis. In our retrospective 
study, USG presented mean of 1.013-1.014 in all 
stages (Table 4). Isosthenuria is one of the findings in 
animals with CKD due to the loss of kidney function in 
concentrating urine. Tubular water loss contributes to 
dehydration, which also worsens when associated with 
anorexia, vomiting, and diarrhea lead by CKD [38,44].
Proteinuria in patients with CKD is due to an 
impaired glomerular filtration related to its damaged 
barrier [17]. It is considered a useful marker of the 
disease progression once it is an indirect measurement 
of renal function loss [21,55]. One of the most used 
methods to quantify non-specific proteinuria is through 
(UPC) which is also used in combination with SBP to 
classify CKD into substages [57].
In the present study, the urine test strip revealed 
approximately 90% of the animals had proteinuria, 
also in agreement with its UPC concentrations, thus 
corroborating with literature data [21]. The degree 
of proteinuria is one of the main hallmarks of CKD 
[21,38], thus in the present study, dogs with higher pro-
teinuria also presented a higher stage of kidney disease, 
therefore, supporting a direct correlation between the 
degree of proteinuria and loss of renal function, leading 
to a reserved prognosis (Table 5). One of the reasons 
might be derived from the occurrence of epithelial 
to mesenchymal transition on tubular epithelial cells 
which contributes with tubulointerstitial damage and 
fibrosis of the kidney [6].
Patients with CKD have the Renin-Angioten-
sin-Aldosterone System (RAAS) activated as a tempt 
to restore the hemodynamic status and thus GFR. 
This activation has a secondary effect on the increase 
of SBP of the animal due to vasoconstriction and in-
flammation. Thus, SBP correlates with the presence 
of proteinuria [2,4,32,52]. With the new consensus of 
hypertension [1], and consequently with the update 
of IRIS guidelines for blood pressure substages [22], 
despite there were no significant differences of SBP 
among the groups (Table 5), in our retrospective study, 
dogs with IRIS-CKD Stage 1 to 3 are now substage 
Bilirubin 0.0 (0.0; 1.0) 0.0 (0.0; 1.0) 0.0 (0.0; 1.0) 0.0 (0.0; 1.0) P > 0.05
Hemoglobin 0.5 (0.0; 4.0) 1.0 (0.0; 4.0) 1.0 (0.0; 4.0) 2.0 (0.0; 0) P > 0.05
Leukocytes 0.5 (0.0; 1.0) 0.0 (0.0; 1.0) 0.0 (0.0; 1.0) 0.0(0.0; 1.0) P > 0.05
Table 5. Distribution of the mean and standard deviation (lowest and highest values, respectively) of the urinary 
Protein:Creatinine Ratio (UPC) and Systolic Blood Pressure (SBP) of each IRIS-CKD stages of the canines 
attended at TH-FMVZ-UNESP in the period of 2011-2017.
IRIS-CKD Stages
1 2 3 4 P value
UPC 1.76(0.80; 6.22) 1.59(0.28, 9.48) 2.54(0.22; 21.20) 2.30(0.05; 11.09) P < 0.05
SBP 158.64 ± 24.91 157.50± 37.23 34 157.32 ± 85 163.62 ± 34.00 P > 0.05
6                                                                                                           J.F.A. Ribeiro, T.T.A. Liguori, A.N.V. Le Sueur, et al. 2020. A Transversal Study of Biochemical Profile, Urinalysis, UPC, Electrolytes 
and Blood Pressure in Dogs with Chronic Kidney Disease. Acta Scientiae Veterinariae. 48: 1733.
as prehypertensive patients (SBP between 140 to 159 
mmHg) and dogs at the end-stage were substage as 
hypertensive (SBP between 160 to 179 mmHg). Fai-
lure in managing hypertension may contribute to the 
intensification of inflammation, and consequently, to 
kidney fibrosis. Hence, the management of systemic 
hypertension is essential to prevent the progression of 
CKD [1,22,23].
This study had some limitations, firstly, GFR 
evaluation was solely measured by serum creatinine 
concentrations, and since SDMA was validated by 
IRIS as a novel kidney biomarker in diagnosing and 
monitoring CKD in 2016, we suggest that SDMA 
would increase the number of non-azotemic dogs 
(IRIS-CKD Stage 1) that were not included in this 
study. Secondly, iCa and FGF-23 analysis suggest a 
better evaluation of bone and mineral disorder of dogs 
with CKD. Unfortunately, our chemistry machine 
does not perform iCa as a routine exam. Therefore, a 
blood gas analyzer would be more suitable for such. 
Moreover, the evaluation of FGF-23 is costly and only 
available for research purposes. At last, the evaluation 
of reticulocyte and erythropoietin concentrations could 
better demonstrate the progression of anemia and blood 
cell regeneration of these animals.
CONCLUSION
In conclusion, CKD diagnosis, staging, and 
monitoring can be achieved with the sum of clini-
cal evaluations, history and imaging findings, SBP 
measurement, and laboratory results such as serum 
creatinine, serum phosphorus, iCa, CBC, USG and 
UPC in a stable and hydrated patient. With the proper 
diagnostic, staging and substaging, these parameters 
can be monitored, predicting longevity and good qua-
lity of life, or progression of the disease with a more 
reserved prognosis.
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